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Background: Atrial fibrillation (AF) is an important preventable cause of stroke. Anticoagulation
(AC) therapy can reduce this risk. However, prescribing patterns and outcomes in patients with
non-valvular AF (NVAF) from Latin American countries are poorly described.
Methods: Using data from the Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF),
we examined the stroke prevention strategies and the 1-year outcomes in patients from four
Latin American countries: Argentina, Brazil, Chile, and Mexico.
Results: A total of 4162 patients (2010-2014) were included in this analysis. At the time of AF
diagnosis, 39.9% of patients were prescribed vitamin K antagonists (VKA) ± antiplatelet
(AP) therapy, 21.8% non-VKA oral anticoagulant (NOAC) ± AP, 24.1% AP only and 14.1% no
antithrombotic treatment. The proportion of moderate-high risk patients receiving no AC ther-
apy at participating centers was highest in Mexico (46.4%) and lowest in Chile (14.3%). During
1-year follow-up, the rates of all-cause mortality, stroke/SE and major bleeding were: 5.77 (95%
CI) (5.06-6.56), 1.58 (1.23-2.02), and 0.99 (0.72-1.36) and per 100 person-years, respectively,
which are higher than the global rates across all countries in GARFIELD-AF. Unadjusted rates of
all-cause mortality were highest in Argentina, 6.95 (5.43-8.90), and lowest in Chile, 4.01
(2.92-5.52).
Conclusions: GARFIELD-AF results describes the marked variation in the baseline characteris-
tics and patterns of antithrombotic treatments in patients with NVAF in four Latin American
countries. Over one-third of patients with a moderate-to-high risk of stroke received no AC
therapy, highlighting the need for improved management of patients according to national
guideline.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia encoun-
tered in clinical practice, with non-valvular AF (NVAF) comprising the†A complete list of the investigators are given in the Appendix.
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majority of cases.1 The prevalence of AF is increasing in both devel-
oped and developing countries, owing to an aging population, and this
increase is predicted to continue over the coming decades.2
Patients with AF have a 5-fold greater risk of stroke and fre-
quently present in elderly patients. Common risk factors for stroke are
hypertension, diabetes, heart failure, smoking, and prior stroke or
transient ischemic attack (TIA).3,4 In addition to an increased risk of
stroke, AF patients frequently present with comorbid myocardial
infarction, dementia, and chronic kidney disease.5,6
The Global Anticoagulant Registry in the FIELD-AF (GARFIELD-
AF) is an ongoing prospective, international, multicentre registry of
adult patients with newly diagnosed NVAF and one or more additional
risk factors for stroke.7 Since December 2009, more than 50 000
patients have been enrolled in the registry from 35 countries and
patient follow-up is anticipated to end in the third quarter of 2018.
Major goals of the registry are to identify best practices as well as
deficiencies in stroke prevention strategies for AF patients and to
describe how patient care has evolved over time. As in all registries,
there might be substantial regional and intraregional differences
among baseline characteristics and use of antithrombotic therapies in
patients with new NVAF.8
In 2010, the Global Burden of Disease Study estimated that age-
adjusted prevalence of AF in Latin America was 737.9 per 100 000
men and 440.3 per 100 000 women, which is higher than the global
average estimated to be 596 per 100 000 men and 373 per 100 000
women.9 It is likely that the true prevalence of AF, in general, may be
even higher due to asymptomatic or unrecognized AF, which is esti-
mated to account for up to 27% undiagnosed AF patients.10
In this paper, we analyzed the baseline characteristics, patterns of
antithrombotic therapies and 1-year outcomes in four Latin American
countries, Argentina, Brazil, Chile, and Mexico that participated in the
GARFIELD-AF.
2 | METHODS
2.1 | Study design and participants
GARFIELD-AF is a non-interventional, observational, worldwide study
of NVAF, as described in detail previously.7 Patients (≥18 years) were
diagnosed with AF according to standard local procedures within the
previous 6 weeks and had at least 1 additional factor(s) for stroke as
judged by the study investigator. Risk factors were not pre-specified in
the protocol nor were they limited to the components of existing risk
stratification schemes. The study excluded patients with a transient,
reversible cause of NVAF, and patients for whom follow-up to 2 years
was not envisaged or possible.7 Consecutive patients were enrolled
prospectively into five sequential cohorts (plus one retrospective
cohort of 5000 patients). Investigator sites were randomly selected11
and were representative of the care settings in each country.
2.2 | Data collected at baseline
Baseline data from the patients were collected at the time of diagnosis
and included the type of AF, patient demographics, medical history,
cardiovascular risk factors, care setting speciality and location, anti-
thrombotic therapy regimen in treated patients, and the main reasons
for not providing anticoagulant treatment in untreated patients. Inter-
national normalized ratio values (INRs) were collected during the first
year of follow-up. Stroke risk was assessed according to CHA2DS2-
VASc (cardiac failure, hypertension, age ≥ 75 [doubled], diabetes,
stroke [doubled]-vascular disease, age 65-74 and sex category
[female]), and bleeding risk according to HAS-BLED (hypertension,
abnormal renal/liver function, stroke, bleeding history or predisposi-
tion, elderly [> 65 years], drugs/alcohol concomitantly) score.12,13
Case report forms (CRFs) were submitted to the registry-
coordinating center (Dendrite Clinical Systems Ltd, Henley-on-
Thames, UK), and the corresponding data were analyzed by an inde-
pendent statistician. All CRFs were examined by the coordinating
center to ascertain completeness and accuracy, and data queries were
sent to participating sites. The data used in the study were extracted
from the database on October 18, 2017.
2.3 | Definitions
AC includes vitamin K antagonists (VKAs) and non-vitamin K antago-
nist oral anticoagulants (NOACs). The term NOAC includes oral direct
factor Xa inhibitors (FXas) and oral direct thrombin inhibitors (DTIs).
Vascular disease is defined as peripheral artery disease and/or coro-
nary artery disease with a history of acute coronary syndrome
(ACS).14 Moderate-to-severe chronic kidney disease (CKD) includes
stage III to stage V according to the National Kidney Foundation's Kid-
ney Disease Outcomes Quality Initiative guidelines.15
2.4 | Ethics statement
Independent ethics committee and hospital-based institutional
review board approvals were obtained, as necessary, for the registry
protocol. The registry is being performed in accordance with the
principles of the Declaration of Helsinki, local regulatory require-
ments, and the International Conference on Harmonization-Good
Pharmacoepidemiological and Clinical Practice guidelines. All
patients gave written informed consent to participate. Confidential-
ity and anonymity of all patients recruited into this registry are
maintained at all times.
2.5 | Statistical analysis
In this analysis, descriptive summaries of patient baseline characteris-
tics were performed for each country, and for all countries taken
together. Continuous variables are presented with mean and SDs, and
numbers of non-missing observations are included in the tables and
figures. Categorical variables are presented using frequencies and per-
centages. Baseline differences between countries were evaluated
using χ2 tests for categorical variables, and Students t-test for contin-
uous variables. Percentages are rounded to one decimal place.
Occurrences of rate mortality are described using the person-time
event rate (per 100 person-years) and 95% CI. We estimated person-
year rates using a Poisson model, with the number of events as the
dependent variable and the log of time as an offset, that is, a covariate
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with a known coefficient of 1. A log-rank test was used to evaluate
whether at least one country varied in mortality rates compared to
the other countries. Stroke/SE and major bleed events were too few
for comparison between countries. Due to the large sample size, small
differences in results can be statistically significant, thus, clinically
important differences are also considered. Data analysis was per-
formed with SAS statistical software, release 9.4 (SAS Institute Inc.,
Cary, North Carolina).
2.6 | INRs and time in therapeutic range
Patients receiving VKA therapy at enrolment with ≥3 INR readings
and for whom time in therapeutic range (TTR) could be calculated
were included in the analysis.16 Patient-level TTR was calculated using
linear interpolation between consecutive INR readings according to
Rosendaal et al17 and using 2.0 to 3.0 as the target INR range.
3 | RESULTS
3.1 | Patient population
A total of 4162 patients with NVAF aged ≥18 years were enrolled in
GARFIELD-AF from 113 randomly selected sites in Argentina, Brazil,
Chile, and Mexico between August 2010 and July 2016. Nine hundred
and fifty-four patients were enrolled at 24 sites in Argentina, 1065 at
41 sites in Brazil, 987 at 16 sites in Chile and 1156 at 32 sites in Mex-
ico. In Argentina, the majority of AF patients were managed in the pri-
vate sector (87.1%) compared with a minority of patients from Chile
(14.6%). Most patients in GARFIELD-AF were enrolled by cardiolo-
gists (Argentina [88.2%], Brazil [82.3%], Mexico [80.7%]), except in
Chile, where the diagnosis and management of AF was shared by car-
diologists (47.8%), internal medicine specialists (26.3%) and general
practitioners (23.9%).
3.2 | Risk factors
Baseline characteristics of patients are shown in Table 1. The mean
age of patients at the time of diagnosis of AF overall was
69.8 ± 12.0 years, and 52.5% were men. The proportion of patients
<65 years of age at the time of diagnosis of AF was highest in Brazil
(36.4%), and the proportion of patients ≥75 years of age was highest
in Chile (45.1%).
One-quarter of the patients had diabetes mellitus (24.6%), and
one-third were current or previous smokers (32.8%). Obesity (body
mass index [BMI] >30 kg/m2) was more common in Argentina (39.8%)
and Chile (39.5%) than Mexico (31.4%) or Brazil (29.1%).
Across all four countries, common associated risk factors for
stroke included hypertension in 81.0% of patients, congestive heart
failure (CHF) in 20.3% of patients, and vascular disease in 14.4% of
patients. The prevalence of vascular disease at the time of diagnosis
of AF was higher in Brazil (17.1%) than Chile (9.3%). More patients
from Mexico had experienced a prior stroke or TIA (16.5%) compared
with patients from Brazil (11.5%), Chile (9.8%), and Argentina (7.4%).
The prevalence of moderate-to-severe CKD ranged from 4.5% in
Argentina to 9.0% in Brazil (Table 1). Despite these differences, the
mean (SD) CHA2DS2-VASc score was similar in patients from Argen-
tina, Brazil, Chile, and Mexico: 3.5 (1.6), 3.3 (1.5), 3.2 (1.7), and 3.1
(1.5), respectively.
3.3 | Antithrombotic treatment for stroke
prevention
Upon diagnosis of AF, 39.9% of patients from all four countries were
prescribed VKAs ± AP therapy, 21.8% NOACs ± AP therapy and
24.1% AP alone. 14.1% of patients received no antithrombotic treat-
ment (Table 2).
Notable differences in patterns of antithrombotic treatment were
found between the countries. The use of NOAC ± AP was higher in
Mexico (28.8%) and Brazil (25.8%) than in Argentina (19.3%) and Chile
(12.3%). The choice of NOAC prescribed also varied between the
countries (Table 2). The proportion of patients who did not receive
any antithrombotic treatment was highest in Brazil (19.2%) and Argen-
tina (17.8%) followed by Mexico (12.0%) and Chile (7.6%).
The proportion of patients receiving VKA ± AP was markedly
higher in Chile (70.0%) than other countries (Argentina [39.7%], Brazil
[28.8%], and Mexico [24.3%]). The proportion of patients receiving
APs only was higher in Mexico (34.9%) and lower in Chile (10%).
Figure 1A presents the antithrombotic treatment received at
baseline by the CHA2DS2-VASc score. Overall, 49.9% of patients with
a moderate-to-severe stroke risk (CHA2DS2-VASc score of ≥2)
received AC ± AP, 23.8% received AP alone and 12.1% did not
receive any antithrombotic treatment. The number of patients who
were not prescribed AC ± AP and had a moderate-high risk of stroke
(CHA2DS2-VASc score of ≥2) was highest in Mexico (46.4%) and low-
est in Chile (14.3%). The proportion of patients with a CHA2DS2-VASc
score of 0 to 1 who did not receive AC ± AP treatment was highest in
Argentina (55.1%).
Figure 1B presents antithrombotic treatment received at baseline
by HAS-BLED score. As the HAS-BLED score increased, the percent-
age of patients receiving antithrombotic therapy decreased. Patients
with a HAS-BLED score of ≥4 more frequently received AP (39.6%)
compared to patients with a HAS-BLED score of 0 (0%), 1 (13.2%),
2 (34.2%) and 3(33.1), respectively.
3.4 | Reasons for anticoagulant therapy was
not used
The main reason for not giving an AC to patients at moderate-to-high
risk of stroke varied between countries but was most frequently the
physician's choice (53.8%) (Table S1, Supporting Information).
3.5 | INR and TTR values
The distribution of INR and TTR values for patients receiving VKA ±
AP at baseline is presented in Table S2. For four countries in Latin
America, a total of 7636 INR readings were included, with a mean
value of 2.3. Overall, 37.2% of the INR values were in the therapeutic
range (2.0 to 3.0). A greater proportion of INR values were <2.0
(46.6%) than >3.0 (16.2%). The mean TTR range was 43.4%
(SD 25.7%) based on data from 744 patients.
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TABLE 1 Baseline characteristics of patients with atrial fibrillation from Argentina, Brazil, Chile, and Mexico and all patients
Argentina
N = 954
Brazil
N = 1065
Chile
N = 987
Mexico
N = 1156
All
N = 4162
P-
value
Age, mean (SD), years 69.7 (11.2) 67.8 (12.7) 71.5 (11.2) 70.3 (12.3) 69.8 (12.0) <0.001
Age, n (%) <0.001
<65 285 (29.9) 388 (36.4) 226 (22.9) 333 (28.8) 1232 (29.6)
65-74 332 (34.8) 322 (30.2) 316 (32.0) 345 (29.8) 1034 (31.5)
≥75 337 (35.3) 355 (33.3) 445 (45.1) 478 (41.3) 1268 (38.6)
Gender, n (%) 0.002
Male 534 (56.0) 587 (55.1) 504 (51.1) 562 (48.6) 2187 (52.5)
Female 420 (44.0) 478 (44.9) 483 (48.9) 594 (51.4) 1975 (47.5)
Ethnicity, n (%)a
Caucasian 285 (30.1) 509 (52.9) 60 (6.1) 15 (1.3) 869 (21.4)
Hispanic/Latino 663 (69.9) 318 (33.1) 921 (93.3) 1100 (95.2) 3002 (74.1)
Asian (not Chinese) 0 (0.0) 8 0.8) 1 (0.1) 0 (0.0) 9 (0.2)
Chinese 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.0)
Afro-Caribbean 0 (0.0) 33 (3.4) 0 (0.0) 1 (0.1) 34 (0.8)
Mixed/other 0 (0.0) 93 (9.7) 5 (0.5) 40 (3.5) 138 (3.4)
Type of AF diagnosed, n (%) <0.001
New 491 (51.5) 555 (52.1) 370 (37.5) 375 (32.4) 1791 (43.0)
Paroxysmal 215 (22.5) 271 (25.4) 317 (32.1) 280 (24.2) 1083 (26.0)
Persistent 69 (7.2) 152 (14.3) 200 (20.3) 202 (17.5) 623 (15.0)
Permanent 179 (18.8) 87 (8.2) 100 (10.1) 299 (25.9) 665 (16.0)
Diabetes, n (%) 174 (18.2) 269 (25.3) 253 (25.6) 327 (28.3) 1023 (24.6) <0.001
Hypercholesterolemia, n (%) b 350 (38.8) 418 (41.8) 361 (40.1) 383 (34.1) 1512 (38.5) 0.002
Current/previous smoker, n (%) c 334 (35.9) 323 (32.2) 281 (30.0) 380 (33.2) 1318 (32.8) 0.021
BMI >30 kg/m2, n (%)d 289 (39.8) 224 (29.1) 243 (39.5) 331 (31.4) 1087 (34.4) <0.001
Pulse (bpm), mean(SD)e 96.7 (31.1) 89.9 (27.8) 89.2 (27.0) 81.2 (20.7) 88.8 (27.2)
Systolic blood pressure (mm Hg), mean
(SD)f
130.5 (18.4) 130.0 (21.5) 135.0 (21.8) 129.9 (19.7) 131.2 (20.5)
Diastolic blood pressure (mm Hg),
mean (SD)f
78.2 (12.1) 78.8 (13.0) 79.6 (14.5) 77.3 (11.4) 78.4 (12.7)
CV medical history, n (%)
Hypertension, n (%)g 770 (81.1) 856 (80.7) 841 (85.5) 892 (77.2) 3359 (81.0) <0.001
Congestive heart failure 168 (17.6) 274 (25.7) 163 (16.5) 241 (20.8) 846 (20.3) <0.001
Vascular disease h 146 (15.3) 181 (17.1) 92 (9.3) 181 (15.7) 600 (14.4) <0.001
Carotid occlusive disease i 20 (2.1) 43 (4.2) 12 (1.2) 31 (2.7) 106 (2.6) <0.001
CV comorbidities
Stroke/TIA 71 (7.4) 123 (11.5) 97 (9.8) 191 (16.5) 482 (11.6) <0.001
Moderate-to-severe CKD j 43 (4.5) 96 (9.0) 62 (6.3) 77 (6.7) 278 (6.7) <0.001
History of bleedingk 42 (4.4) 48 (4.5) 26 (2.6) 53 (4.6) 169 (4.1) 0.078
Pulmonary embolism/DVTl 17 (1.8) 31 (3.0) 18 (1.8) 35 (3.0) 101 (2.4) 0.099
Systemic embolismm 5 (0.5) 13 (1.3) 17 (1.7) 14 (1.2) 49 (1.2) 0.109
Moderate-heavy alcohol consumption,
n (%)n
45 (5.3) 96 (9.0) 62 (6.3) 77 (6.7) 278 (6.7) <0.001
Cirrhosis, n (%)o 0 (0.0) 3 (0.3) 4 (0.4) 8 (0.7) 15 (0.4) 0.073
CHA2DS2-VASc score categories, n(%) <0.001
0 20 (2.1) 38 (3.7) 30 (3.1) 28 (2.4) 116 (2.8)
1 115 (12.3) 128 (12.5) 96 (9.9) 110 (9.6) 449 (11.0)
2 225 (24.0) 177 (17.4) 153 (15.7) 184 (16.0) 739 (18.1)
3 226 (24.1) 241 (23.6) 233 (23.9) 249 (21.6) 949 (23.3)
4 203 (21.7) 226 (22.2) 259 (26.6) 310 (26.9) 998 (24.5)
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3.6 | Event rates at 1-year follow-up
Overall, event rates per 100 person-years were highest for all-
cause mortality (5.77; 95% CI: 5.06-6.56), followed by stroke/SE
(1.58; 95% CI: 1.23-2.02), and major bleeding (0.99; 95% CI:
0.72-1.36), respectively. Death (n = 228) was most frequently car-
diovascular related (46.9%), 35.1% were non-cardiovascular
related, and 18.0% were an undetermined cause. Table 3 shows the
unadjusted rates of all-cause mortality and cause of death in each
country.
4 | DISCUSSION
In this paper, we describe the baseline characteristics, antithrombotic
treatment patterns, quality of VKA control and event rates for major
clinical outcomes in AF patients from four countries in Latin America,
who were enrolled in the GARFIELD-AF registry.
Even though patients were from the same region, the baseline
characteristics and comorbidities were remarkably different for
patients from each country. Patients from Chile, for example, were
typically older than other in this countries analysis, with a higher inci-
dence of obesity, although these patients had a lower incidence of
vascular disease. Interestingly, a history of stroke and TIA was more
than twice as frequent in Mexico (16.5%) compared with patients
from Argentina (7.4%).
At the time of AF diagnosis, there were also major differences in
the choice of AC treatment for stroke prophylaxis in Argentina, Brazil,
Chile, and Mexico. The prescription of antithrombotic therapy was
highest in Chile where most patients received VKA ± AP (70.0%)
rather than NOACs ± AP (12.3%). This was in contrast to Mexico,
where prescription of NOACs ± AP was more common (28.8%), with a
smaller number of patients receiving VKA ± AP (24.3%). These differ-
ences might be related to the differences in patients recruited in
countries, differences in enrolling sites and public or private health
policies at each country.
Although key guidelines in Latin America, including the Brazilian
Society of Cardiology 2009 (BSC),18 the Brazilian Cardiogeriatrics
Society (BCS)19 and the Latin-American Society of Cerebrovascular
Diseases20 recommend the use of a VKA as the main oral AC in AF
patients at high risk of stroke and stress the importance of assessing
the embolic and bleeding risks, the prescription of AC therapy was
low and there was still a high use of antiplatelets as an alternation to
AC for stroke prevention.
It has been demonstrated that the benefit of AC therapy signifi-
cantly outweighs the risk of bleeding for AF patients with a CHADS2
or CHA2DS2-VASc score of ≥2.
21–23 In GARFIELD-AF, over four-fifths
TABLE 1 (Continued)
Argentina
N = 954
Brazil
N = 1065
Chile
N = 987
Mexico
N = 1156
All
N = 4162
P-
value
5 99 (10.6) 111 (10.9) 124 (12.7) 148 (12.9) 482 (11.8)
6-9 48 (5.1) 99 (9.7) 78 (8.0) 122 (10.6) 347 (8.5)
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; DVT, deep vein thrombosis; TIA. transient ischaemic attack.
aData unavailable for 109 patients.
bData unavailable for 237 patients.
cData unavailable for 148 patients.
dData unavailable for 1003 patients.
eData unavailable for 236 patients.
fData unavailable for 230 patients.
gData unavailable for 13 patients.
hData unavailable for 7 patients.
iData unavailable for 62 patients.
jData unavailable for 1 patient.
kData unavailable for 9 patients.
lData unavailable for 32 patients.
mData unavailable for 318 patients.
nData unknown for 99 patients.
oData unavailable for 82 patients.
TABLE 2 Anticoagulation treatment patterns at baseline
Argentina (n = 949) Brazil (n = 1041) Chile (n = 976) Mexico (n = 1140) All (n = 4106)
VKA, % 26.3 19.8 53.9 18.6 29.1
VKA + AP, % 13.4 9.0 16.1 5.7 10.8
FXaI, % 8.0 16.3 6.9 17.0 12.3
FXaI + AP, % 3.2 4.8 3.3 3.6 3.7
DTI, % 6.0 3.3 1.6 6.9 4.5
DTI + AP, % 2.1 1.4 0.5 1.4 1.3
AP, %a 23.2 26.2 10.1 34.9 24.1
No treatment 17.8 19.2 7.6 12.0 14.1
Abbreviations: AP, antiplatelets; DTI, direct thrombin inhibitor; FXaI, Factor Xa inhibitor; VKA,vitamin K antagonist.
The P-value for at least one country having a different treatment mix is < 0.001.
aAP alone.
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of patients from Latin America were classified as having a moderate-
to-high risk of stroke (ie, CHA2DS2-VASc score ≥ 2). Of these
patients, 35.9% did not receive an anticoagulant. It is widely accepted
that AC reduces stroke risk in AF patients; VKAs reduce the risk of
stroke by 66% and the risk of death by 28% compared to no therapy.1
Despite this evidence, AC remains widely underused in this analysis of
four Latin American countries. Moreover, of patients with a low risk
of stroke (ie, a CHA2DS2-VASc score < 2), approximately half (49.9%)
received AC therapy, which indicates overuse of AC in these patients.
These figures emphasize the requirement for improved adherence to
guidelines with regards to the antithrombotic treatment for stroke
prevention. This underuse of OAC is similar to the published reports
from other registries in the past decade.24
In this registry, the primary reason for patients at high risk of
stroke not receiving a VKA was the physician's choice. This may be
due to concerns regarding patient’s compliance with therapy or risks
of bleeding, especially in elderly patients. It has been shown previ-
ously that when considering VKA prescription, physicians may
FIGURE 1 A, Antithrombotic treatment at baseline by CHA2DS2-VASc score for all patients in Argentina, Brazil, Chile and Mexico. B,
Antithrombotic treatment at baseline by HAS-BLED score for all patients in Argentina, Brazil, Chile and Mexico. AP, antiplatelet; DTIs, direct
thrombin inhibitors; FXas, factor Xa inhibitors; VKAs, vitamin K antagonists
TABLE 3 Mortality at 1-year follow-up
Cause of death, n (% of total deaths)
All-cause mortality rate (95% CI)
per 100-person years* Cardiovascular Non-cardiovascular Undetermined
Total number
of deaths
Mexico (N = 1187) 5.91 (4.63-7.53) 33 (50.8%) 16 (24.6%) 16 (24.6%) 65
Brazil (N = 1065) 6.19 (4.83-7.94) 24 (38.7%) 25 (40.3%) 13 (21.0%) 62
Argentina (N = 954) 6.95 (5.43-8.90) 28 (44.4%) 26 (41.3%) 9 (14.3%) 63
Chile (N = 987) 4.01 (2.92-5.52) 22 (57.9%) 13 (34.2%) 3 (7.9%) 38
All (N = 4162) 5.77 (5.06-6.56) 107 (46.9%) 80 (35.1%) 41 (18.0%) 228
*Log rank P-value = 0.03; The P-value tests whether mortality is different in at least one country.
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overestimate the risk of bleeding and underestimate the benefit of
stroke prevention. The underutilization of AC therapy in AF patients
may also be perpetuated by misperceptions of the safety and efficacy
of aspirin in AF.25
The efficacy and safety of VKAs are heavily reliant on the inten-
sity of anticoagulation, as measured by the INR. INR readings during
1-year follow-up were analyzed for VKA-treated patients with ≥3
measurements. Among the measured values in this registry, only
37.2% were in the therapeutic range (2.0-3.0), whereas 46.6% of the
INR values were <2.0 and 16.2% were >3. These figures are in mar-
ked contrast to in the findings from clinical trials, comparing NOACs
to warfarin, where there was a strong emphasis in accomplishing ade-
quate INRs. Thus, in the ROCKET-AF trial, 55% of INR values in Latin
American patients were in the therapeutic range.26 Similarly in the
ENGAGE-AF trial, 62% of Latin American patients were in therapeutic
range.27 In GARFIELD-AF, there were almost two-times as many INR
readings of <2, indicating an increased risk of ischemic stroke in the
population of patients included in this analysis. Although the use of
VKAs varied among the four countries the mean TTRs were similarly
low, in contrast to what is recommended in international guide-
lines.1,28 Thus, it is likely that sub-optimal TTR may contribute to
poorer outcomes in patients from four countries of Latin America
which is in accordance with the previously published data from
GARFIELD-AF registry.16 VKA use requires regular monitoring, patient
education, access to coagulation clinics, consistence in the VKAs pro-
vided through the public health systems. All these conditions may not
be feasible to achieve in many parts of Latin America, due to patient
access to healthcare or service costs or low education levels which
are contributing to poor patient compliance. Additionally, we only
have one presentation of warfarin (5 mg) and acenocoumarin (4 mg)
tablets, making dosage difficult for patients. Moreover, the use of
generics of different qualities is now common practice in public health
systems in Latin America. Thus, sub-optimal TTR obtained has multi-
ple factors.
It has been suggested that in patients with a TTR <65%, the use
of NOACs is likely to provide significant clinical benefits.29 Indeed,
the use of NOACs in AF patients would eliminate the requirement for
frequent monitoring, which may limit the use of AC therapy in many
regions of Latin America. Challenges in improving the prescribing of
this new class of drugs include: patient education25 and lack of ade-
quate public health policies related to the cost of NOACs, which may
be unaffordable for many regions in Latin America,30 although several
pharmaco-economic studies have shown NOACs to be more cost-
effective than VKAs in Latin America.31,32 NOAC use is likely to
increase in coming years, given their favorable safety and efficacy pro-
file, as guidelines are updated.33 The new Brazilian Guideline from
201634 and Mexican Guidelines,23 for example, indicates the use of
NOACs in a similar manner to the European guidelines. This has also
been stressed by different groups of Latin American investigators.35,36
All-cause mortality was the most frequent major clinical outcome,
nearly 4-fold higher than the rate of stroke/SE, and 6-fold higher than
the rate of major bleeding. Mortality rates from the combined experi-
ence: Argentina, Brazil, Chile, and Mexico are higher to those reported
in the entire GARFIELD-AF registry.37 However, these numbers are
consistent with other reports from Latin America, derived from clinical
trials, such as ENGAGE-AF and ROCKET-AF.27,38 In addition to the
poor management of antithrombotic therapies, it is possible that the
reasons for the high mortality rates of Latin American patients with
AF are related to a higher rate of comorbidities or sociocultural prob-
lems, such as difficulties in access to healthcare, lower educational
levels, etc. Considering the AC treatment underuse, poor VKA control,
and high mortality rate which are challenge for our health systems,
developing countries should be warned and achieve their evidence. If
our results are reproduced, strategies should be established to
improve AF patient care. Whatever the reasons, there is room for
improvement in the management of AF patients in Argentina, Brazil,
Chile, and Mexico.
5 | LIMITATIONS
This registry is limited to patients with newly diagnosed AF and the
study was mainly conducted by the cardiologists. As with all registries,
there may be a bias in the selection of patients and medical centers
and so the results may not reflect the experience in all centers in
these countries.
6 | CONCLUSIONS
This paper describes the baseline characteristics and patterns of anti-
thrombotic treatment in patients from four Latin American countries,
Argentina, Brazil, Chile, and Mexico. Over one-third of patients with a
moderate-to-high risk of stroke received no AC therapy, highlighting
the need for better adherence to evidence-based guidelines on stroke
prevention in AF.
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